Hematology and Hematopathology
- Communiqué: Newly Diagnosed Multiple Myeloma: Cytogenetic Classification
- Communiqué: A Combined Cytoplasmic Immunoglobulin Staining and FISH Method (cIg FISH) to Detect Prognostic Genetic Anomalies in Multiple Myeloma and Related Plasma Cell Proliferative Disorders
- Communiqué: Polycythemia Vera
- Communiqué: FISH Analysis Provides Important Prognostic Information in B-Cell Chronic Lymphocytic Leukemia
- Mayo Clinic Video: Polycythemia Vera (PV)
- Mayo Clinic Video: Myelofibrosis Update
- Hot Topic: Classic Myeloproliferative Neoplasms
Mayo Clinic Links
Questions or comments about our laboratory?
Acute Myeloid Leukemia (AML), FISH
(Test ID: FAML)
Acute myeloid leukemia (AML) is 1 of the most common adult leukemias, with almost 10,000 new cases diagnosed per year. AML also comprises 15% of pediatric acute leukemias and accounts for the majority of infant (<1 year old) leukemias. Several subtypes of AML have been recognized (termed AML-M0, M1, M2, M3, M4, M5, M6, and M7) based on the malignant myeloid cell lineage involved. In addition to morphology, several recurrent chromosomal anomalies have been linked to specific subtypes of AML.
Testing of Hematopoietic Neoplasms
The cytogenetics laboratory is directed by physician laboratorians who understand the clinical testing needs and complexities of appropriate test integration for all aspects of patient management, including diagnosis, prognosis, and therapy monitoring. This expertise is available to Mayo Medical Laboratories' clients through interpretive reporting and consultative services. Specialized tests required for the management of patients with hematopoietic disorders are rigorously validated and continuously monitored to ensure reliable, high-quality results. The molecular and cytogenetic laboratories work collaboratively to offer a comprehensive and practical test menu.
Optimal Test Utilization
A cellular pellet is saved in the cytogenetic laboratory for potential future testing if subsequent clinical questions arise or if other studies point to the need for further analysis with fluorescence in situ hybridization (FISH) probes. The laboratory supports ongoing development and continues to incorporate innovative platforms and testing strategies to expand the test menu as clinical needs arise.
The cytogenetic laboratory for congenital and hematologic analysis has played a leading role in establishing fluorescence in situ
hybridization (FISH) as an important clinical technique. A large group of
board-certified genetic counselors are also available to assist with hereditary genetic questions that may arise.
- Umut Aypar, PhD, Co-Director
- Patricia T. Greipp, DO, Co-Director
- Nicole L. Hoppman, PhD, Co-Director
- Hutton Kearney, PhD, Co-Director
- Rhett P. Ketterling, MD, Co-Director
- Robert B. Jenkins, MD, PhD, Co-Director
- William R. Sukov, MD, Co-Director
- Erik C. Thorland, PhD, Co-Director
- Daniel L. Van Dyke, PhD, Co-Director